Safety and immunogenicity of typhoid fever and yellow fever vaccines when administered concomitantly with quadrivalent meningococcal acwy glycoconjugate vaccine in healthy adults

Journal of Travel Medicine

Volumn 22, Issue 1, 2015, Pages 48-56

  Alberer, Martin ^a   Burchard, Gerd ^b   Jelinek, Tomas ^c   Reisinger, Emil ^d   Beran, Jiri ^e   Hlavata, Lucie Cerna ^f   Forleo Neto, Eduardo ^f   Dagnew, Alemnew F ^f   Arora, Ashwani K ^g  

^a UNIVERSITY OF MUNICH   (Germany)

^b UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^c Berlin Center for Travel and Tropical Medicine   (Germany)

^d UNIVERSITY OF ROSTOCK   (Germany)

^e Vaccination and Travel Medicine Centre   (Czech Republic)

^f Novartis Vaccines and Diagnostics Inc   (United States)

^g NOVARTIS VACCINES AND DIAGNOSTICS   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

MENINGOCOCCUS VACCINE; NEUTRALIZING ANTIBODY; TYPHOID VACCINE; YELLOW FEVER VACCINE; BACTERIAL POLYSACCHARIDE; MENACWY-CRM VACCINE; TYPHOID PARATYPHOID VACCINE; VACCINE; VI POLYSACCHARIDE VACCINE, TYPHOID;

ADULT; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; CONTROLLED STUDY; CZECH REPUBLIC; DRUG FATALITY; DRUG SAFETY; EMPORIATRICS; ENZYME LINKED IMMUNOSORBENT ASSAY; FATIGUE; FEMALE; FLU LIKE SYNDROME; GERMANY; HEADACHE; HEALTH PROGRAM; HUMAN; HUMAN EXPERIMENT; IMMUNOGENICITY; INJECTION SITE PAIN; LIMB PAIN; MALE; MENINGOCOCCOSIS; MULTICENTER STUDY; NEISSERIA MENINGITIDIS; NORMAL HUMAN; PHASE 3 CLINICAL TRIAL; PNEUMONIA; RANDOMIZED CONTROLLED TRIAL; SALMONELLA ENTERICA SEROVAR TYPHI; SERODIAGNOSIS; SERUM BACTERICIDAL ANTIBODY ASSAY; TONSILLITIS; TOOTH DISEASE; TYPHOID FEVER; YELLOW FEVER; YELLOW FEVER VIRUS; ANTIBODY PRODUCTION; CLINICAL TRIAL; IMMUNIZATION; IMMUNOLOGY; MENINGOCOCCAL INFECTIONS; MIDDLE AGED; PROCEDURES; TRAVEL; VACCINATION; YOUNG ADULT;

ADULT; ANTIBODY FORMATION; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HEALTHY VOLUNTEERS; HUMANS; IMMUNIZATION SCHEDULE; MALE; MENINGOCOCCAL INFECTIONS; MENINGOCOCCAL VACCINES; MIDDLE AGED; NEUTRALIZATION TESTS; POLYSACCHARIDES, BACTERIAL; SERUM BACTERICIDAL ANTIBODY ASSAY; TRAVEL; TYPHOID FEVER; TYPHOID-PARATYPHOID VACCINES; VACCINATION; VACCINES, CONJUGATE; YELLOW FEVER; YELLOW FEVER VACCINE; YOUNG ADULT;

EID: 84931572229     PISSN: 11951982     EISSN: 17088305     Source Type: Journal    
DOI: 10.1111/jtm.12164     Document Type: Article

References (41)

1. Cooper B, DeTora L, Stoddard J,. Menveo®: a novel quadrivalent meningococcal crm197 conjugate vaccine against serogroups A, C, W-135 and Y. Expert Rev Vaccines 2011; 10: 21-33.
2. World Health Organization. Meningococcal meningitis. Fact sheet 141. 2012. Available at: http://www.Who.Int/mediacentre/factsheets/fs141/en/. (Accessed 2014 Mar 14).
3. Jafri RZ, Ali A, Messonnier NE, et al. Global epidemiology of invasive meningococcal disease. Popul Health Metr 2013; 11: 17.
4. Black SB, Plotkin SA,. Meningococcal disease from the public health policy perspective. Vaccine 2012; 30 (Suppl 2): B37-B39.
5. Steffen R,. The risk of meningococcal disease in travelers and current recommendations for prevention. J Travel Med 2010; 17 (Suppl): 9-17.
6. Koch S, Steffen R,. Meningococcal disease in travelers: vaccination recommendations. J Travel Med 1994; 1: 4-7.
7. Hedari CP, Khinkarly RW, Dbaibo GS,. Meningococcal serogroups A, C, W-135, and Y tetanus toxoid conjugate vaccine: a new conjugate vaccine against invasive meningococcal disease. Infect Drug Resist 2014; 7: 85-99.
8. Broker M, Dull PM, Rappuoli R, Costantino P,. Chemistry of a new investigational quadrivalent meningococcal conjugate vaccine that is immunogenic at all ages. Vaccine 2009; 27: 5574-5580.
9. Stamboulian D, Lopardo G, Lopez P, et al. Safety and immunogenicity of an investigational quadrivalent meningococcal CRM(197) conjugate vaccine, MenACWY-CRM, compared with licensed vaccines in adults in Latin America. Int J Infect Dis 2010; 14: e868-e875.
10. Gill CJ, Baxter R, Anemona A, et al. Persistence of immune responses after a single dose of novartis meningococcal serogroup A, C, W-135 and Y CRM-197 conjugate vaccine (Menveo®) or Menactra® among healthy adolescents. Hum Vaccin 2010; 6: 881-887.
11. Cohn AC, MacNeil JR, Clark TA, et al. Prevention and control of meningococcal disease: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2013; 62 (RR-2): 1-28.
12. Memish ZA, Goubeaud A, Broker M, et al. Invasive meningococcal disease and travel. J Infect Public Health 2010; 3: 143-151.
13. Harrison LH, Pelton SI, Wilder-Smith A, et al. The global meningococcal initiative: recommendations for reducing the global burden of meningococcal disease. Vaccine 2011; 29: 3363-3371.
14. Parry CM, Hien TT, Dougan G, et al. Typhoid fever. N Engl J Med 2002; 347: 1770-1782.
15. Centers for Disease Control and Prevention. Typhoid fever. 2013. Available at: http://wwwnc.Cdc.Gov/travel/diseases/typhoid. (Accessed 2014 Mar 14).
16. Johnson KJ, Gallagher NM, Mintz ED, et al. From the CDC: New country-specific recommendations for pre-travel typhoid vaccination. J Travel Med 2011; 18: 430-433.
17. Staples JE, Gershman M, Fischer M,. Yellow fever vaccine: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2010; 59 (RR-7): 1-27.
18. Monath TP, Cetron MS,. Prevention of yellow fever in persons traveling to the tropics. Clin Infect Dis 2002; 34: 1369-1378.
19. Cetron MS, Marfin AA, Julian KG, et al. Yellow fever vaccine: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2002. MMWR Recomm Rep 2002; 51 (RR-17): 1-11 quiz CE1-4.
20. Jentes ES, Poumerol G, Gershman MD, et al. The revised global yellow fever risk map and recommendations for vaccination, 2010: consensus of the informal WHO working group on geographic risk for yellow fever. Lancet Infect Dis 2011; 11: 622-632.
21. World Health Organization. International health regulations. World Health Organization, 2005. Available at: http://www.who.int/csr/ihr/en/. (Accessed 2014 Mar 14).
22. Lang J, Zuckerman J, Clarke P, et al. Comparison of the immunogenicity and safety of two 17D yellow fever vaccines. Am J Trop Med Hyg 1999; 60: 1045-1050.
23. Pfister M, Kursteiner O, Hilfiker H, et al. Immunogenicity and safety of BERNA-YF compared with two other 17D yellow fever vaccines in a phase 3 clinical trial. Am J Trop Med Hyg 2005; 72: 339-346.
24. Goldschneider I, Gotschlich EC, Artenstein MS,. Human immunity to the meningococcus II. Development of natural immunity. J Exp Med 1969; 129: 1327-1348.
25. Caugant DA, Maiden MC,. Meningococcal carriage and disease-population biology and evolution. Vaccine 2009; 27 (Suppl 2): B64-B70.
26. Christensen H, May M, Bowen L, et al. Meningococcal carriage by age: a systematic review and meta-analysis. Lancet Infect Dis 2010; 10: 853-861.
27. Reisinger KS, Baxter R, Block SL, et al. Quadrivalent meningococcal vaccination of adults: phase III comparison of an investigational conjugate vaccine, MenACWY-CRM, with the licensed vaccine, Menactra. Clin Vaccine Immunol 2009; 16: 1810-1815.
28. Nascimento Silva JR, Camacho LA, Siqueira MM, et al. Mutual interference on the immune response to yellow fever vaccine and a combined vaccine against measles, mumps and rubella. Vaccine 2011; 29: 6327-6334.
29. Jong EC, Kaplan KM, Eves KA, et al. An open randomized study of inactivated hepatitis A vaccine administered concomitantly with typhoid fever and yellow fever vaccines. J Travel Med 2002; 9: 66-70.
30. Nasveld PE, Marjason J, Bennett S, et al. Concomitant or sequential administration of live attenuated Japanese encephalitis chimeric virus vaccine and yellow fever 17D vaccine: randomized double-blind phase II evaluation of safety and immunogenicity. Hum Vaccin 2010; 6: 906-914.
31. Klein NP, Reisinger KS, Johnston W, et al. Safety and immunogenicity of a novel quadrivalent meningococcal CRM-conjugate vaccine given concomitantly with routine vaccinations in infants. Pediatr Infect Dis J 2012; 31: 64-71.
32. Klein NP, Shepard J, Bedell L, et al. Immunogenicity and safety of a quadrivalent meningococcal conjugate vaccine administered concomitantly with measles, mumps, rubella, varicella vaccine in healthy toddlers. Vaccine 2012; 30: 3929-3936.
33. Gasparini R, Conversano M, Bona G, et al. Randomized trial on the safety, tolerability, and immunogenicity of MenACWY-CRM, an investigational quadrivalent meningococcal glycoconjugate vaccine, administered concomitantly with a combined tetanus, reduced diphtheria, and acellular pertussis vaccine in adolescents and young adults. Clin Vaccine Immunol 2010; 17: 537-544.
34. Arguedas A, Soley C, Loaiza C, et al. Safety and immunogenicity of one dose of MenACWY-CRM, an investigational quadrivalent meningococcal glycoconjugate vaccine, when administered to adolescents concomitantly or sequentially with Tdap and HPV vaccines. Vaccine 2010; 28: 3171-3179.
35. Haq K, McElhaney JE,. Immunosenescence: influenza vaccination and the elderly. Curr Opin Immunol 2014; 29C: 38-42.
36. Lang PO, Govind S, Bokum AT, et al. Immune senescence and vaccination in the elderly. Curr Top Med Chem 2013; 13: 2541-2550.
37. Lord JM,. The effect of ageing of the immune system on vaccination responses. Hum Vaccin Immunother 2013; 9: 1364-1367.
38. Furman D, Hejblum BP, Simon N, et al. Systems analysis of sex differences reveals an immunosuppressive role for testosterone in the response to influenza vaccination. Proc Natl Acad Sci U S A 2014; 111: 869-874.
39. Pennell LM, Galligan CL, Fish EN,. Sex affects immunity. J Autoimmun 2012; 38: J282-J291.
40. Klein SL, Poland GA,. Personalized vaccinology: one size and dose might not fit both sexes. Vaccine 2013; 31: 2599-2600.
41. Klein SL, Jedlicka A, Pekosz A,. The Xs and Y of immune responses to viral vaccines. Lancet Infect Dis 2010; 10: 338-349.